Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. Cancer Discov 2014 Feb;4(2):155-65
Date
01/21/2014Pubmed ID
24441285Pubmed Central ID
PMC3946319DOI
10.1158/2159-8290.CD-13-0197Scopus ID
2-s2.0-84893439855 (requires institutional sign-in at Scopus site) 82 CitationsAbstract
UNLABELLED: Normal-tissue adverse effects following radiotherapy are common and significantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.
SIGNIFICANCE: A single-nucleotide polymorphism–based predictive assay could be used, along with clinical and treatment factors, to estimate the risk that a patient with cancer will develop adverse effects from radiotherapy. Such an assay could be used to personalize therapy and improve quality of life for patients with cancer.
Author List
Kerns SL, Ostrer H, Rosenstein BSAuthor
Sarah L. Kerns PhD Associate Professor in the Radiation Oncology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
BiomarkersGenome-Wide Association Study
Genomics
Humans
Neoplasms
Polymorphism, Single Nucleotide
Prognosis
Radiation Injuries
Radiation Tolerance
Radiotherapy
